These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38226018)

  • 1. Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets.
    Wang J; Zhao Y; Liao P; Huang S; Huang Y; Chen S; Li Y; Zhong L
    Blood Sci; 2024 Jan; 6(1):e00181. PubMed ID: 38226018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma.
    Huang S; Zhao Y; Liao P; Wang J; Li Z; Tan J; Zha X; Chen S; Li Y; Zhong L
    Front Oncol; 2022; 12():1014904. PubMed ID: 36439426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased exhausted CD8
    Tan J; Chen S; Huang J; Chen Y; Yang L; Wang C; Zhong J; Lu Y; Wang L; Zhu K; Li Y
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e266-e274. PubMed ID: 29943497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma.
    Brauneck F; Weimer P; Schulze Zur Wiesch J; Weisel K; Leypoldt L; Vohwinkel G; Fritzsche B; Bokemeyer C; Wellbrock J; Fiedler W
    Front Med (Lausanne); 2021; 8():763773. PubMed ID: 34820398
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
    Huang S; Liang C; Zhao Y; Deng T; Tan J; Zha X; Li Y; Chen S
    Cytometry B Clin Cytom; 2022 Mar; 102(2):143-152. PubMed ID: 34913594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
    Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
    Front Immunol; 2019; 10():1638. PubMed ID: 31379838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML.
    Tan J; Yu Z; Huang J; Chen Y; Huang S; Yao D; Xu L; Lu Y; Chen S; Li Y
    Biomark Res; 2020; 8():6. PubMed ID: 32082573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of immune checkpoint proteins in HPV-infected cervical cancer.
    Zou W; Huang R; Li P; Liu X; Huang Q; Yue J; Liu C
    J Infect Public Health; 2023 Apr; 16(4):542-550. PubMed ID: 36801634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased TOX expression associates with exhausted T cells in patients with multiple myeloma.
    Zhao Y; Liao P; Huang S; Deng T; Tan J; Huang Y; Zhan H; Li Y; Chen S; Zhong L
    Exp Hematol Oncol; 2022 Mar; 11(1):12. PubMed ID: 35246241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
    BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 and TIGIT Are Highly Co-Expressed on CD8
    Xu L; Liu L; Yao D; Zeng X; Zhang Y; Lai J; Zhong J; Zha X; Zheng R; Lu Y; Li M; Jin Z; Hebbar Subramanyam S; Chen S; Huang X; Li Y
    Front Oncol; 2021; 11():686156. PubMed ID: 34490086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 in T cells from patients with non-Hodgkin lymphoma.
    Huang S; Liang C; Zhao Y; Deng T; Tan J; Lu Y; Liu S; Li Y; Chen S
    Asia Pac J Clin Oncol; 2022 Feb; 18(1):143-149. PubMed ID: 33608984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased TIGIT
    Luo Q; Fu P; Guo Y; Fu B; Guo Y; Huang Q; Huang Z; Li J
    Exp Ther Med; 2022 Oct; 24(4):642. PubMed ID: 36160887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the immune checkpoint receptor TIGIT in seminoma.
    Hinsch A; Blessin NC; Simon R; Kluth M; Fischer K; Hube-Magg C; Li W; Makrypidi-Fraune G; Wellge B; Mandelkow T; Debatin NF; Höflmayer D; Lennartz M; Sauter G; Izbicki JR; Minner S; Büscheck F; Uhlig R; Dum D; Krech T; Luebke AM; Wittmer C; Jacobsen F; Burandt E; Steurer S; Wilczak W
    Oncol Lett; 2019 Aug; 18(2):1497-1502. PubMed ID: 31423216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis.
    Nakayama C; Tanoue K; Idichi T; Shimomura H; Kita Y; Hozaka Y; Shinden Y; Matsushita D; Nakajo A; Arigami T; Mataki Y; Kurahara H; Ohtsuka T
    Anticancer Res; 2022 Jul; 42(7):3373-3380. PubMed ID: 35790289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia.
    Zhang X; Zhang H; Chen L; Feng Z; Gao L; Li Q
    Cell Immunol; 2019 Oct; 344():103958. PubMed ID: 31376919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8
    Wang M; Bu J; Zhou M; Sido J; Lin Y; Liu G; Lin Q; Xu X; Leavenworth JW; Shen E
    Clin Immunol; 2018 May; 190():64-73. PubMed ID: 28893624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma.
    Lozano E; Mena MP; Díaz T; Martin-Antonio B; León S; Rodríguez-Lobato LG; Oliver-Caldés A; Cibeira MT; Bladé J; Prat A; Rosiñol L; Fernández de Larrea C
    Clin Cancer Res; 2020 Sep; 26(17):4688-4698. PubMed ID: 32513837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.